|
Session 195-Poster Abstracts
New HIV Prevention Strategies and Modeling of Impact
Wednesday, 2-4 pm; Poster Hall |
959
 |
Demographic, Behavioral, and Clinical Characteristics of HIV-1 Serodiscordant Couples Enrolled into an Efficacy Trial of Pre-exposure Prophylaxis
Jared Baeten*1, P Ndase1, N Mugo1,2, D Donnell3, A Mujugira1, L Kidoguchi1, L Barnes1, C Celum1, and Partners PrEP Study Team
1Univ of Washington, Seattle, US; 2Univ of Nairobi, Kenya; and 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, US |
960
|
HIV Partner Notification is Feasible in Sub-Saharan Africa with a High Yield of Newly Diagnosed HIV Infection
Lillian Brown*1,2, W Miller2, G Kamanga1, N Nyirenda1, P Mmodzi1, C Mapanje1, A Pettifor2, F Martinson1, M Cohen2, and I Hoffman2
1UNC Project, Lilongwe, Malawi and 2Univ of North Carolina at Chapel Hill, US |
961
|
Declines in Partners Exposed to Risk of HIV Infection: The CDC Prevention in Care Settings Study
Lytt Gardner*1, G Marks1, C O’Daniels2, T Wilson3, C Golin4, B Quinlivan4, J Wright5, M Thompson6, and M Thrun7
1CDC, Atlanta, GA, US; 2Carter Consulting Corp, Atlanta, GA, US; 3State Univ of New York, Brooklyn US; 4Univ of North Carolina at Chapel Hill, US; 5Univ of Missouri-Kansas City, US; 6AIDS Res Consortium of Atlanta, GA, US; and 7Denver Publ Hlth, CO, US |
| 962 |
Cost-effectiveness of Early Use of Antiretrovirals for Prevention and Treatment of HIV Infection
Jonathan Anderson* and D Cooper
Natl Ctr in HIV Epi and Clin Res, Sydney, Australia |
963
|
Potential Impact of Recent Infections, HIV Testing and Start of Antiretroviral Drugs at a CD4 of <350 on the HIV Epidemic in a Rural Area in Zambia: A Mathematical Model
David van de Vijver*1, J van Dijk2, J Nouwen1, J van de Wijgert3, D Frentz1, P Thuma2, J Lange3, and C Boucher1
1Erasmus Med Ctr, Univ Med Ctr Rotterdam, The Netherlands; 2Macha Mission Hosp and Macha Res Trust, Zambia; and 3Academic Med Ctr and Amsterdam Inst for Global Hlth and Devt, The Netherlands |
964
|
Test and Treat: Forecasting the Clinical and Epidemiological Impact of Expanded HIV Screening and Immediate ART in Sub-Saharan Africa
Callie Scott*1, X Anglaret2,3, R Walensky1,4, E Ouattara2,3, D Paltiel5, C Danel2,3, A Stoler1, S Eholie6, G Seage7, and K Freedberg1,4,7
1Massachusetts Gen Hosp, Boston, US; 2INSERM U897, Univ Bordeaux 2, France; 3Prgm PACCI, Abidjan, Côte d`Ivoire; 4Harvard Med Sch, Boston, MA, US; 5Yale Sch of Med, New Haven, CT, US; 6Ctr Hosp Univ Treichville, Abidjan, Côte d`Ivoire; and 7Harvard Sch of Publ Hlth, Boston, MA, US |
965
|
Economic Analysis of ART for Prevention of HIV Transmission in a South African Generalized HIV Epidemic Setting
R Granich1, James Kahn*2, R Bennett3, M Sabin1, C Holmes4, N Garg5, C Makhlouf-Obermeyer1, C DeFilippo Mack6, S Crowley1, B Williams7, and the ART IMPACT Study Group
1WHO, Geneva, Switzerland; 2Univ of California, San Francisco, US; 3Independent Consultant, London, UK; 4Dept of State, Washington, DC, US; 5Vestergaard-Frandsen, Lausanne, Switzerland; 6Univ of North Carolina at Chapel Hill, US; and 7South African Ctr for Epi Modelling and Analysis, Stellenbosch |
| 966 |
A “Test and Treat” Strategy In South Africa Is Likely to Lead to a Self-sustaining Epidemic Composed of Only NNRTI-resistant Strains
Sally Blower*1, J Kahn2, and J Okano1
1David Geffen Sch of Med, Univ of California, Los Angeles, US and 2Univ of California, San Francisco, US |
|
